Biofrontera Q3 revenue rises 30% on higher Ameluz sales
Overview
US biopharma firm's Q3 revenue rose 30% yr/yr to $9.1 mln
Company posted Q3 net loss of $6.4 mln, slightly improved from prior year
Q3 adjusted EBITDA loss narrowed to $5.5 mln from $6.0 mln last year
Outlook
Company preparing to commercialize Ameluz for sBCC in late Q4 2026 and early Q1 2027
Company submitted supplemental New Drug Application to expand Ameluz label for actinic keratosis
Result Drivers
AMELUZ UNIT VOLUME - Co said revenue growth was primarily due to a 23.3% increase in Ameluz unit volume, with additional contributions from price/mix and device sales
ACCELERATED CUSTOMER ORDERS - Co said part of the unit volume increase was driven by customers accelerating orders in anticipation of potential supply restrictions from the ITC exclusion order
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $9.1 mln | $8.50 mln (1 Analyst) |
Q3 Loss Per Share | $0.42 | ||
Q3 Net Loss | $6.4 mln | ||
Q3 Adjusted EBITDA | -$5.5 mln | -$1.40 mln (1 Analyst) |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Biofrontera Inc is $3.00, about 224% above its November 12 closing price of $0.93
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 84 three months ago
Reuters Recommended Reads
Nov 12 - Verrica reports narrower-than-expected Q3 adjusted loss per share, YCANTH revenue grows
Nov 12 - Israeli dermatology firm Sol-Gel's Q3 net loss narrows on lower R&D expenses
Nov 12 - Journey Medical's Q3 revenue rises on Emrosi demand but misses estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)